TWI239846B - Remedies comprising water extracts of a mushrooms as an effective ingredient - Google Patents

Remedies comprising water extracts of a mushrooms as an effective ingredient Download PDF

Info

Publication number
TWI239846B
TWI239846B TW091115842A TW91115842A TWI239846B TW I239846 B TWI239846 B TW I239846B TW 091115842 A TW091115842 A TW 091115842A TW 91115842 A TW91115842 A TW 91115842A TW I239846 B TWI239846 B TW I239846B
Authority
TW
Taiwan
Prior art keywords
mushrooms
factor production
neurotrophic factor
enhancing
feed
Prior art date
Application number
TW091115842A
Other languages
Chinese (zh)
Inventor
Hiromu Ohnogi
Katsumi Sugiyama
Hiroaki Sagawa
Ikunoshin Kato
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of TWI239846B publication Critical patent/TWI239846B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

According to the present invention, there is provided a therapeutic agent or prophylactic agent that is effective for a disease requiring enhancement of nerve growth factor production for treatment or prevention, comprising as an effective ingredient an aqueous extract of mushrooms. These agents are usable in the treatment or prevention of a disease requiring enhancement of nerve growth factor production such as dementia or nerve disorder. In addition, according to the present invention, there is provided an enhancing agent for growth factor production, or a food, beverage or feed for enhancing nerve growth factor production, each comprising the above-mentioned effective ingredient. According to the food or beverage, by taking as a foodstuff on a daily basis, the symptoms of a disease requiring enhancement of nerve growth factor production can be ameliorated or the like. In addition, the feed is useful for maintaining homeostasis of a living body by its enhancing action for nerve growth factor production.

Description

1239846 ,_, (1) 發明說明續頁 的神經性營養因子。此與阿茲海默爾氏病型癡呆症的關連 備受注目（Pharmasia，vol· 22, No· 2, 147-151 ( 1986)，老年精神 醫學，vol· 3，Νο· 6, 75 1-758 ( 1986))。 阿茲海默爾氏病型癡呆症是指隨著發育障礙、躁症狀、 下肢痙攣、癲癇型發作等臨床現象，有老人斑、阿茲海默 爾氏原線維變化等病理學所見之疾病，是老人性痴呆之一 種病型。儘管近年來由於高齡化社會傾向之增加，人們對 社會賦予重大關心，如此症狀的改善法及治療法仍尚未被 發現。還有，關於年輕性阿茲海默爾氏病之症狀改善法及 治療法尚未被發現。 阿茲海默爾氏病型癡呆症患者腦中 被認為於以Mynelt 基底核為中心之前腦基底部有顯著的變性，以及乙醯膽鹼 轉移酶（CAT)活性顯著降低之症狀（Annu. Rev· Neurosci·，Vol. 3, 77 (1980))。1985年在使用老鼠腦所做的研究中，明白地 顯示出NGF是於腦此部位中之神經性營養因子（EMBO J.， Vol· 4, 13 89 ( 1985))。於是NGF與本疾病之關連被受到注目 。此外，亨廷頓舞蹈疾病者腦中之線條體明顯地隨者GABA 作動性神經細胞脫落的同時，膽鹼作動性神經細胞也脫落 ，被發現NGF對於線條體之内在性，作動性神經細胞亦有 作用（Science，Vol· 234，1341 ( 1986))於是本疾病被指出與 N GF之關聯的可能性。於得到各種神經疾病模型之老鼠等 動物試驗代表中被研究其NGF效果，已有報導指出若於老 鼠神經細胞變性變為顯著之前將NGF投予腦内，則可抑制 變性、防止 CAT活性下降（J· Neurosci·，Vol. 6，2155 (1986)、 1239846 (2) 發興麵續灰·1239846, _, (1) Description of the invention Continuing neurotrophic factors. This association with Alzheimer's disease type dementia is highly noticeable (Pharmasia, vol. 22, No. 2, 147-151 (1986), Geriatric Psychiatry, vol. 3, No. 6, 75 1- 758 (1986)). Alzheimer's disease type dementia refers to diseases seen in pathologies such as plaques of the elderly, changes in the dimensions of the Alzheimer's line along with clinical phenomena such as developmental disorders, manic symptoms, cramps in the lower limbs, and seizures. A form of Alzheimer's disease. Although in recent years, due to the increasing tendency of an aging society, people have paid great attention to society, and methods to improve and treat such symptoms have not yet been found. In addition, there are no methods to improve the symptoms and treatment of young Alzheimer's disease. Patients with Alzheimer's dementia are thought to have significant degeneration of the basal part of the brain before the center of the basal nucleus of Mynelt, as well as symptoms of significantly reduced acetylcholine transferase (CAT) activity (Annu. Rev Neurosci., Vol. 3, 77 (1980)). In a 1985 study using mouse brains, it was clearly shown that NGF is a neurotrophic factor in this part of the brain (EMBO J., Vol. 4, 13 89 (1985)). So the relationship between NGF and this disease has been noticed. In addition, the striatal body in the brain of Huntington's disease patients apparently fell off with the GABA acting nerve cells, and the choline acting nerve cells also fell off. It was found that NGF has an effect on the internality of the striatal body and the acting nerve cells. (Science, Vol. 234, 1341 (1986)) Then the possibility of this disease being linked to NGF was pointed out. The NGF effect has been studied in animal test representatives such as mice that have obtained various neurological disease models. It has been reported that if NGF is injected into the brain before the neuronal degeneration of mice becomes significant, it can inhibit degeneration and prevent CAT activity from decreasing ( J. Neurosci ·, Vol. 6, 2155 (1986), 1239846 (2) Fascination continues

Brain Res·，Vol. 293, 305 (1985)、Science，Vol· 235, 214 (1986)、 Proc. Natl· Acad· Sci· USA, Vol. 83, 923 1 (1986))。而且被證明 出於末梢交感神經支配組織和腦當中有NGF之生化合成 ，而其中為末梢組織或腦組織之間質細胞的線維芽細胞或 星型神經膠質細胞於此NGF之生化合成中，擔當有各種重 要角色（J. Bol· Chem·，Vol· 259，1259 (1984)、Biochem· Biophys· Res. Commun·，Vol· 136, 57 (1986))。還有，隨著此線維芽細胞 或星型神經膠質細胞產生之NGF的抗原性、分子量、等電 點、生物活性等，被發現和過去曾經研究過之顎下腺N G F 相同，同時，從於線維芽細胞（L-M細胞）及星型神經膠質 細胞之培養液中加入各種神經傳達物質的實驗中，亦被發 現鄰苯二酚胺（降腎上腺素、腎上腺素、多巴胺）具有NGF 合成促進效果（J· Biol· Chem.，Vol. 201，6039 (1986))。 如此一來，以N G F為神經性營養因子，於作用部位變性 之此些神經疾病中，被期待NGF是否能以為抑制變性之治 療藥使用。還有，由於腦血管障害、腦腫瘍、腦尖、頭部 外傷變性疾病、麻醉藥物中毒等一旦腦神經細胞變性即無 法恢復生涯。其結果儘管會造成知性機能下降、記憶障礙 之外，會引起感情障礙、行動異常等各種障礙，因為神經 纖維具可塑性，一旦損傷從其附近完好纖維會再發芽，而 損害之突觸會換成新的突觸，此時NGF被期待是否可以為 促進神經機能再生修復之治療劑使用。 惟在N G F被應用於各種神經疾病之治療的情況，N G F非 得到達需要NGF之神經細胞極附近不可，且於中樞神經疾 發明說明續頁 1239846 (9) 本發明對於必需要有NGF產生增強之疾病的治療劑或 預防劑，可列舉與本發明相關之前述有效成分與公告之醫 藥用擔體搭配而製劑化後之物。 本發明之治療劑或預防劑的製造，通常將前述有效成分 與在藥理學上許可之液狀及固狀擔體配合而成。還有，依 所希望加入溶劑、分散劑、乳化劑、緩衝劑、安定劑、賦 形劑、結合劑、崩壞劑、滑澤劑等 使之為錠劑、顆粒劑 、散劑、粉末劑、膠囊劑等之固形劑、通常液劑、懸濁劑 、乳劑等之液劑。還有，可由於使用前添加適當擔體，使 之為非液狀之乾燥品或其他外用劑。 醫藥用擔體可按照治療劑或預防劑之服用方式及劑型 選擇。於由固體組成物構成之經口劑的情況下，可為錠劑 、丸劑、膠囊劑、散劑、細粒劑、顆粒劑等。例如，在擔 體方面可利用澱粉、乳糖、白糖、甘露糖醇、羧甲基纖維 素、玉米澱粉、無機鹽等。還有於經口劑之調製方面，可 再和結合劑、崩壞劑、界面活性劑、潤澤劑、流動性促進 劑、矯味劑、著色劑、香料等配合。例如於錠劑或丸劑的 情況下，依所希望可被覆蔗糖、明膠、羧基丙基纖維素等 之糖衣或胃溶性或腸溶性物質之膜亦可。在由液體組成物 構成之經口劑的情況下，可為在藥理學上被應許之乳濁劑 、溶液劑、懸濁劑、糖漿等。例如，精製水、乙醇等可當 擔體被利用。還有，可再依所希望添加濕潤劑、像懸浮劑 樣的補助劑、甘味劑、風味劑、防腐劑等。 另一方面，在非經口劑的情況下，依照常法將本發明前 -15 - 1239846 (10) 杳豳說胡磺頁； V y - ^i-V -1· , ^ ^ 述之有效成分於注射用蒸餾水、生理食鹽水、葡萄糖水溶 液、注射用植物油、麻油、落花生油、大豆油、玉米油、 丙二醇、聚乙二醇等之稀釋劑中非溶解而讓其懸濁，依所 希望經由添加殺菌劑、安定劑、等張化劑、無痛化劑等加 以調製。還有，製造固體組成物，並於使用前將之溶解於 無菌水或無菌注射用溶劑加以使用亦可。 外用劑包含經皮投藥用或經黏膜（口腔内、鼻腔内）投藥 用之固體、半固體狀或液狀之製劑。還有，亦包含座劑。 例如可為乳劑、洗淨劑等之乳濁劑、外用藥g了、經黏膜投 藥用液劑等之液狀製劑、油性軟膏、親水性軟膏等之軟膏 劑、膜劑、貼劑、外敷軟膏等之經皮投藥用或經黏膜投藥 用之貼付劑等。 以上之各種製劑，可利用各種公告之醫藥用擔體等適宜 地依照常法製造。還有，於如此之製劑其有效成分之含有 量，考慮其投藥型態、投藥方法等，理想狀況是只要在後 述之投藥量範圍内能夠將當該有效成分投入之量的話，並 無被限制。 本發明之治療劑或預防劑，應製劑之型態循適當地投藥 路徑被投入。投藥方法無特別限制，可由内用、外用及注 射之方式。注射劑可投入於靜脈内、筋肉内、皮下、皮内 等，外用劑可例如將座劑依適當方法投入即可。 本發明之治療劑或預防劑的投入量依照其製劑型態、投 入方法、使用目的及當該治療劑或預防劑之投入對象的患 者年齡、體重、症狀等適當地被設定，並無一定。一般而 -16- 1239846 (Π) 言，被含於製劑中之前述有效成分的投入量，理想狀況為 成人一日約0.1 pg-200 mg/kg。當然因為投入量依各種條件 有所變動，有較上述投入量量少之情況，或者亦有有必要 超過範圍之情況。投藥於所希望之投藥量範圍内，一曰一 次，或者分開數次亦可。投藥期間亦可任意。還有，本發 明之治療劑或預防劑可就其原封不動經口投藥，或者添加 於任意飲食品中讓其被日常攝取亦可。 還有，本發明亦可提供含有上述有效成分之NGF產生增 強劑。該增強劑可為前述有效成分本身，亦可為含有前述 有效成分之組成物。NGF產生增強劑，例如將前述有效成 分和當有效成分相同用途上，與可以使用之其他成分等相 配合，再以上述治療劑或預防劑之製造方法為基準，以通 常被使用試藥的形態製造即可。於如此之增強劑其前述有 效成分之含有量，考慮該增強劑之投藥方法、使用目的等 ，只要是能達到本發明所期待之效果即可，並無被特定限 制。還有，該增強劑之使用量也是只要能得到本發明所希 望之效果，無特別的限定。特別是投藥於身體内的情況， 理想狀況是於前述治療劑或預防劑有效成分之投藥量範 圍内，投入有效成分即可。NGF產生增強劑對於必須有 NGF產生增強的疾病，該成長因子之增強非常有用。還有 ，該增強劑對於和NGF相關疾病之藥物篩選也有用。再者 該增強劑對於與NGF或神經細胞之物理變化有關的機能 研究亦有用。 還有，本發明提供含有前述有效成分、添加或/及稀釋 -17- 1239846 〇2) 發明巍明續頁 而成之NGF產生增強用食品、飲料或飼料。本發明之食品 、飲料或飼料，由於具有NGF產生增強作用，對於有必要 NGF產生增強之疾病症狀的改善、預防非常有用。 於本發明之食品、飲料或飼料的製造法並無特別限定。 例如配合、調理、加工等遵循一般食品、飲料或飼料即可 ，可依該等製造法製造。只要於得到之食品、飲料及飼料 中被含有具NGF產生增強作用之與本發明相關的前述有 效成分即可。 本發明之食品或飲料並無特別限定。例如可舉例被含有 與本發明相關之前述有效成分之穀類加工物（小麥粉加工 品、澱粉類加工品、增補營養食物加工品、麵類、通心粉 、麵包、紅豆餡類麵包、蕎麥麵類、麵麩、米粉、冬粉、 包裝餅等）、油脂加工品、（可塑性油脂、天婦羅油、沙拉 油、美乃滋類、調味汁等）、大豆加工品（豆腐類、味噌、 納豆等）、食肉加工品（火腿、醺豬肉、火腿腸、香腸等） 、水產製品（冷凍磨碎魚肉、魚糕、竹輪、魚肉山芋丸子 、炸干薯、魚丸、筋、魚内火腿、香腸、乾柴魚、魚卵加 工品、水產罐頭、佃煮等）、乳製品（原料乳、奶油霜、酸 乳酪、黃奶油、起司、煉乳、粉乳、冰淇淋等）、野菜果 實加工品（糊狀類、果醬類、潰類、果實飲料、蔬菜飲料 、混合飲料等）、點心類（巧克力、餅乾類、點心麵包類、 蛋糕、餅菓子、米菓類等）' 酒精飲料（日本酒、中國酒、 葡萄酒、威士忌、燒酒、伏特加、白蘭地、琴酒、萊母酒 、啤酒、清涼酒精飲料、果實酒、甜酒飲料等）、嗜好飲 -18- 1239846 (η) 料（綠茶、紅茶、烏龍茶、咖啡、清涼飲料、乳酸飲料等） ㈣味料（醬油、醬汁、醋、料理酒等）、罐裝瓶裝袋裝食 口 ( 叶 TO (牛飯、蒼飯、紅飯、咖哩飯、其他各種調理畢食品）、 半乾燥或濃縮食品（肝醬、其他塗味食品、蕎麥烏龍麵汁 ;辰縮湯類）、乾燥食品（速食麵、速食咖哩、即溶咖啡、 果汁粉、粉沫湯包、速食味噌湯、調理畢食品、調理畢飲 料、調理畢湯類等）、冷凍食品（壽喜燒、茶碗蒸、燒鰻、 肉餅牛排、燒賣、餃子、各種冷凍半加工食品、水果雞尾 酒等）、固形食品、液體食品（湯等）、香辛料類等之農林 產加工品、屬·產加工品、水產加工品等。 於本發明之食品或飲料中被含有、添加或/及稀釋前述 之有效成分，只要是被含有可發現NGF產生增強作用所必 須的量的話即可，並無特別之形狀限定。板狀、顆粒狀、 膠囊狀等之形狀，只要是能約經口攝取即可。 本發明之食品或飲料中之前述有效成分的含有量無特 定被限制。可從其官能及活性的觀點適宜地選擇。例如於 食品中理想狀況為0.00001重量％以上，更好是〇 〇〇〇1-1〇〇重 量％為佳，0.0006-90重量％特佳。例如於飲料中理想狀況 為0.00001重量％以上’ 0.0001-10重量％為佳，0·0006-6重量0/〇 特佳。還有本發明之食物及飲料於理想狀況下，其含有之 有效成份，例如成人一日攝取0.001-100 mg/kg，mg/ka 為佳。 還有，本發明提供一種含有、被添加及/或稀釋有ngf 產生增強作用之生物用飼料。再者，以別種型態提供一種 -19- 發:頁: 1239846 〇4) 生物飼育方法，其以於生物中投入前述有效成分為特徵。 還有，以為本發明之別種型態被提供一種生物飼育用劑， 其以含有前述有效成分為特徵。 於此等之發明，可舉例之生物例如養殖動物、寵物等。 養殖動物可舉例有家畜、實驗動物、家禽、魚類、甲殼類 及貝類等。飼料可舉例有維持身體狀況及/或改善用飼料 等。生物飼育用劑可舉例有浸潰用劑、飼料添加劑、飲料 用添加劑等。 於此等之發明中被適用之生物，基於被使用之前述有效 成分的NGF產生增強作用，可期待與由本發明中前述治療 劑或預防劑形成相同結果之發現。即，本發明之飼料等於 該生物體中，對於需要NGF產生增強作用之疾病具有治療 或預防效果。 於本發明中被使用之前述有效成分，通常投藥量之理想 狀況為對象生物的體重每1公斤1日約0.01-2000 mg之間。在 投藥方面，例如將供給於對象生物之人工配合飼料的原料 中混合添加本發明之有效成分而得之本發明飼料或人工 配合飼料之粉末原料，與本發明之有效成分混合而得之生 物飼育用劑再混合添加於其他原料中加以調製飼料後，該 飼料予以使用亦可。還有，前述有效成份於飼料中之含有 量，並無特定被限制，以能達到目的適宜地被設定即可。 最好是在0.001-15重量％之比例之間。 在人工配合飼料上，可舉例魚粉、酪蛋白、章魚腸粉等 之動物性原料；大豆粕、小麥粉、澱粉等之植物性原料； -20- 發嘢譁辨續頁 1239846 (15) 飼料用酵母等之微生物原料；鳕魚肝油、烏賊肝油等之動 物性油脂；大豆油、菜種油之植物性油脂；及維他命類、 礦物質類、胺基酸、抗酸化劑等為原料之人工配合飼料。 還有魚肉碎末等之魚類用飼料。 本發明之飼料製造法並無特定限定，及其配合亦與一般 飼料為基準即可。只要是於被製造之飼料中被含具NGF 產生增強作用之與本發明相關的前述有效成分即可。 還有，將具有NGF產生增強作用之與本發明相關的前述 有效成分直接添加於游泳池、水槽、保持桶或者飼育遠域 之水、海水等中，將對象生物浸潰其中投藥亦可。此浸潰 方法是在對象生物之飼料攝取量低時特別有效。於水或海 水中具有NGF產生增強作用之與本發明相關的前述有效 成分在濃度上並無限定，應目的而使用即可。理想狀況以 0.00001-1重量％之比例為適當。 還有，以含有具NGF產生增強作用之本發明前述有效成 分的飲料為飼育用飲料，讓對象生物攝取亦可。該飲料中 之具NGF產生增強作用於本發明中被使用前述有效成分 的濃度無特別限定，可應目的而使用，以0.0001-20重量％ 的比例為適當。含有具NGF產生增強作用之本發明前述有 效成分的生物飼育用劑，例如浸潰用劑、飼料添加劑、飲 料用添加劑，可由個別公告之配合及製造法製造即可。於 該生物飼育用劑之有效成分含有量只要是能達到本發明 所希望之效果，無被特定限制。 可適用於本發明之生物雖無限制，養殖動物上可舉例馬 -21 - 〆知·· . ·* *-··· «^ J f * · 發明說明續頁 1239846 (16) 、牛、緒、羊、山羊、路轮、絡馬等家畜；小鼠、老鼠、 天竺鼠、小白兔等實驗動物；難、鴨、火雞鳥、鴕鳥等家 禽；棘鬣魚、石鯛 '比目魚、鲽魚、·獅魚、青鉗、紅鉗、 鮪魚、竹荚魚、姑魚、經魚。鱒魚類、河豚、縵魚、泥鍊 、鯰魚等魚類；明蝦、黑虎、大頭蝦、梭子蟹等之甲殼類 等；鮑魚、螺、海扇、牡蠣等貝類；及在寵物上可舉例狗 、貓等，可廣泛適用於陸上•水中動物。 可經由攝取含有具NGF產生增強作用於本發明中被使 用之前述有效成分之飼料，或將對象生物浸潰於具NGF 產生增強作用於本發明中被使用之前述有效成分的含有 液中，可維持或改善家畜、實驗動物、家禽、魚類、貝類 、寵物等身體狀況之良好。 再者，以本發明之別種型態，於必須有NGF產生增強之 疾病的治療劑或預防劑、NGF產生增強劑、及NGF產生增 強用食品、飲料、或飼料的製造中，提供與本發明相關之 前述有效成分的使用。相關使用型態可列舉，本發明前述 之治療劑或預防劑、NGF產生增強劑、及NGF產生增強用 食品、飲料、或者於飼料之製造中前述有效成分的使用型 態。例如，N G F產生增強所需疾病之治療劑、預防劑或N G F 產生增強劑之製造中，前述有效成分的使用上，於如前述 之錠劑、顆粒劑、散劑、粉末劑、膠囊劑等之固形劑、通 常液劑、懸濁劑、乳劑等之液劑，以及，由於使用前添加 適當的擔體而得非呈液狀而是乾燥品的製造，其使用被舉 有例示。 -22- zr Λ 、- ' ' ^ 'ί 發明說明續頁 1239846 (23) 產業上利用之可能 於本發明是關於含有蕈類水性萃取物以為有效成分之 治療或預防上提供給必需要增強神經養因子產生之疾病 有效的醫藥、食品、飲料或飼料。Brain Res., Vol. 293, 305 (1985), Science, Vol. 235, 214 (1986), Proc. Natl. Acad. Sci. USA, Vol. 83, 923 1 (1986)). Moreover, it has been proved that there is biochemical synthesis of NGF in peripheral sympathetic innervating tissues and brain, and among these, lineage bud cells or astrocytes of stromal cells between peripheral tissues and brain tissues play a role in this biochemical synthesis of NGF. There are various important roles (J. Bol · Chem ·, Vol · 259, 1259 (1984), Biochem · Biophys · Res. Commun ·, Vol · 136, 57 (1986)). In addition, with the antigenicity, molecular weight, isoelectric point, and biological activity of NGF produced by this line of bud cells or astrocytes, it has been found to be the same as the submandibular gland NGF that has been studied in the past. In the experiments of adding various neurotransmitting substances to the culture medium of line bud cells (LM cells) and astrocytes, it has also been found that catecholamines (norepinephrine, epinephrine, dopamine) have the effect of promoting NGF synthesis ( J. Biol. Chem., Vol. 201, 6039 (1986)). In this way, NGF is used as a neurotrophic factor, and it is expected that NGF can be used as a therapeutic agent for inhibiting degeneration in such neurological diseases as degeneration at the site of action. In addition, due to cerebrovascular disorders, brain swellings, brain apex, degenerative diseases of head trauma, poisoning by anesthetic drugs, etc., once the neurons of the brain degenerate, they cannot resume their careers. As a result, in addition to the decline of intellectual function and memory disorders, it can cause various disorders such as emotional disturbances and abnormal movements. Because nerve fibers are plastic, once the damage is intact, the fibers will sprout again, and the damaged synapses will be replaced by New synapses, at this time NGF is expected to be used as a therapeutic agent to promote neural regeneration and repair. However, in the case where NGF is applied to the treatment of various neurological diseases, NGF cannot be obtained near the nerve cells that require NGF, and it is in the description of central nervous disease invention. Continued on page 1239846 Examples of the therapeutic agent or preventive agent include those in which the aforementioned active ingredient related to the present invention is formulated with a medicinal support for pharmaceutical use. The therapeutic agent or preventive agent of the present invention is usually produced by mixing the aforementioned active ingredient with a liquid and solid support that is pharmacologically acceptable. In addition, if necessary, a solvent, a dispersant, an emulsifier, a buffering agent, a stabilizer, an excipient, a binding agent, a disintegrating agent, a slip agent, and the like are added to make it a tablet, granule, powder, powder, Capsules and other solids, liquids, suspensions, emulsions and other liquids. In addition, it can be made into a non-liquid dry product or other external preparations by adding an appropriate carrier before use. The medical support can be selected according to the way of taking the therapeutic or preventive agent and the dosage form. In the case of oral preparations composed of a solid composition, tablets, pills, capsules, powders, fine granules, granules, and the like can be used. For example, starch, lactose, white sugar, mannitol, carboxymethyl cellulose, corn starch, inorganic salts, and the like can be used for the carrier. In the preparation of oral agents, it can be combined with binding agents, disintegrating agents, surfactants, emollients, flowability promoters, flavoring agents, coloring agents, and fragrances. For example, in the case of lozenges or pills, a sugar coating or a film of a gastric or enteric substance may be coated with sucrose, gelatin, carboxypropyl cellulose, etc. as desired. In the case of an oral preparation composed of a liquid composition, it may be an opacifying agent, a solution, a suspending agent, a syrup and the like which are pharmacologically approved. For example, purified water and ethanol can be used as a carrier. Furthermore, wetting agents, suspending agents, supplements, sweeteners, flavors, preservatives, etc. may be added as desired. On the other hand, in the case of parenteral preparations, according to the usual method, the first -15-1239846 (10) of the present invention is said to be a sulfonide page; V y-^ iV -1 ·, ^ ^ Diluents such as distilled water for injection, physiological saline, dextrose aqueous solution, vegetable oil for injection, sesame oil, groundnut oil, soybean oil, corn oil, propylene glycol, and polyethylene glycol are not dissolved in the diluent, and they are suspended. Bactericides, stabilizers, isotonicity agents, analgesics, etc. are prepared. Alternatively, a solid composition may be produced and used by dissolving it in sterile water or a sterile solvent for injection before use. Topical preparations include solid, semi-solid or liquid preparations for transdermal administration or transmucosal (intraoral, intranasal) administration. It also contains a base. For example, it can be an opacifying agent such as an emulsion, a detergent, a topical drug, a liquid preparation such as a medicinal liquid solution, an ointment, an oily ointment, a hydrophilic ointment, an ointment, a film, a patch, and an external ointment. And other transdermal or transmucosal patches. The above-mentioned various preparations can be appropriately manufactured in accordance with a conventional method by using variously-supported pharmaceutical carriers and the like. In addition, the content of the active ingredient in such a preparation, taking into account the type of administration, the method of administration, etc., ideally, as long as the amount of the active ingredient can be injected within the range of the amount to be described later, it is not limited. . The therapeutic agent or prophylactic agent of the present invention is administered in an appropriate administration route according to the form of the preparation. There are no particular restrictions on the method of administration, and it can be used internally, externally, and by injection. The injection can be administered intravenously, intramuscularly, subcutaneously, intradermally, etc., and the external preparation can be, for example, a base preparation by an appropriate method. The dosage of the therapeutic or preventive agent of the present invention is appropriately set in accordance with the formulation type, the method of administration, the purpose of use, and the age, weight, and symptoms of the patient to whom the therapeutic or preventive agent is to be administered, and is not necessarily set. Generally speaking, -16-1239846 (Π), the dosage of the aforementioned active ingredient contained in the preparation is ideally about 0.1 pg-200 mg / kg per day for an adult. Of course, because the amount of input varies depending on various conditions, it may be smaller than the amount of input mentioned above, or it may be necessary to exceed the range. Dosing is within the desired dosage range, once a day, or several times. The period of administration can also be arbitrary. The therapeutic or preventive agent of the present invention may be administered orally as it is, or it may be added to any food or drink to be taken daily. The present invention also provides an NGF-producing enhancer containing the above-mentioned effective ingredient. The reinforcing agent may be the aforementioned active ingredient itself or a composition containing the aforementioned active ingredient. NGF production enhancer, for example, the aforementioned active ingredient and the same active ingredient are used in combination with other ingredients that can be used, and then based on the manufacturing method of the above-mentioned therapeutic agent or preventive agent, based on the commonly used test drug form Just make it. With regard to the content of the aforementioned effective ingredients of such an enhancer, considering the method of administration and purpose of use of the enhancer, as long as the desired effect of the present invention can be achieved, there is no particular limitation. The amount of the reinforcing agent used is not particularly limited as long as the desired effect of the present invention can be obtained. In particular, when it is administered in the body, it is desirable that the effective ingredient is injected within the range of the amount of the active ingredient of the aforementioned therapeutic or preventive agent. Enhancers of NGF production are useful for diseases where enhanced NGF production is necessary. In addition, the enhancer is also useful for drug screening of NGF-related diseases. Furthermore, the enhancer is also useful for functional studies related to physical changes in NGF or nerve cells. In addition, the present invention provides food, beverage or feed for enhancing NGF production which contains the aforementioned active ingredient, addition or / and dilution -17-1239846 〇2) The invention is continued. The food, beverage or feed of the present invention has an effect of enhancing NGF production, and is very useful for improving and preventing symptoms of diseases that require enhanced NGF production. The manufacturing method of the food, drink, or feed in this invention is not specifically limited. For example, compounding, conditioning, processing, etc. should follow the general food, beverage or feed, and can be manufactured according to these manufacturing methods. As long as the obtained food, beverage and feed contain the aforementioned effective ingredients related to the present invention, which have an enhancement effect of NGF. The food or drink of the present invention is not particularly limited. For example, processed cereals (wheat flour processed products, starch processed products, supplementary food processed products), noodles, macaroni, bread, red bean stuffed bread, buckwheat noodles, Bran, rice noodles, winter flour, packed cakes, etc.), processed oils and fats (plastic oils, tempura oil, salad oil, mayonnaise, sauces, etc.), processed soybeans (tofu, miso, natto, etc.) Meat processing products (ham, pork, ham sausage, sausage, etc.), aquatic products (frozen grated fish meat, fish cake, bamboo wheel, fish meat, potato balls, fried potato, fish ball, tendon, fish ham, sausage, dried Dried fish, processed fish roe, canned aquatic products, braised, etc.), dairy products (raw milk, cream, yogurt, yellow cream, cheese, condensed milk, powdered milk, ice cream, etc.), processed wild fruits (paste, Jams, mashes, fruit drinks, vegetable drinks, mixed drinks, etc.), snacks (chocolate, biscuits, snacks and breads, cakes, cakes, rice crackers, etc.) 'Alcoholic drinks (Japanese wine, Chinese wine, wine, whiskey, shochu, vodka, brandy, gin, rum, beer, refreshing alcoholic beverages, fruit wine, liqueur drinks, etc.), hobby drinks-18-1239846 (η) ingredients (green tea , Black tea, oolong tea, coffee, refreshing beverages, lactic acid beverages, etc.) savory flavors (soy sauce, sauces, vinegar, cooking wine, etc.), canned bottled bagged mouths Curry rice, various other prepared foods), semi-dried or concentrated foods (liver paste, other flavored foods, buckwheat udon sauce; Chen shrink soups), dry foods (instant noodles, instant curry, instant coffee, fruit juice Noodles, noodle soup, instant miso soup, prepared foods, prepared beverages, prepared soups, etc.), frozen foods (Sukiyaki, tea bowl steaming, roast eel, meatloaf steak, yakiniku, dumplings, various frozen half Processed foods, fruit cocktails, etc.), solid foods, liquid foods (soups, etc.), processed agricultural and forestry products such as spices, genus processed products, processed aquatic products, etc. It is used in the food or beverage of the present invention. The aforementioned effective ingredients are added, added, and / or diluted, as long as they are contained in an amount necessary for the enhancement of NGF, and there is no particular limitation on the shape. The shape of plate, granule, capsule, etc. The content of the aforementioned active ingredient in the food or beverage of the present invention is not particularly limited. It can be appropriately selected from the viewpoint of its function and activity. For example, it is 0.00001% by weight in the ideal state in food The above is more preferably 0.001 to 100% by weight, more preferably 0.0006 to 90% by weight. For example, in a beverage, it is preferably 0.00001% by weight or more, and 0.0001 to 10% by weight is preferable, 0.006 -6 weight 0 / 〇 is particularly good. In addition, the food and beverage of the present invention ideally contain effective ingredients, such as 0.001-100 mg / kg, preferably mg / ka for adults. In addition, the present invention provides a biological feed containing ngf which is added, added, and / or diluted. Furthermore, a -19- hair: Page: 1239846 〇 4) biological breeding method is provided in another type, which is characterized by adding the aforementioned active ingredient to the organism. Furthermore, according to another aspect of the present invention, a biofeeding agent is provided, which is characterized by containing the aforementioned active ingredient. Examples of such inventions include living animals, pets, and the like. Examples of farm animals include livestock, laboratory animals, poultry, fish, crustaceans, and shellfish. Examples of the feed include feed for maintaining physical condition and / or improving. Examples of the biofeeding agent include an impregnating agent, a feed additive, and a beverage additive. The organism to which the invention is applied has an enhancement effect based on the NGF of the aforementioned active ingredient used, and the discovery that the same result as the aforementioned therapeutic or preventive agent in the present invention can be expected. That is, the feed of the present invention is equivalent to the organism having a therapeutic or preventive effect on a disease requiring an enhancement effect of NGF. The ideal dosage of the aforementioned active ingredient used in the present invention is usually about 0.01-2000 mg per 1 kg of body weight of the target organism. In terms of administration, for example, the raw material of artificial compound feed supplied to the target organism is mixed with the active ingredient of the present invention, or the powder raw material of the artificial compound feed is mixed with the active ingredient of the present invention. After the agent is mixed and added to other raw materials to prepare a feed, the feed may be used. In addition, the content of the aforementioned active ingredients in the feed is not particularly limited, and may be appropriately set so as to achieve the purpose. It is preferably between 0.001 and 15% by weight. Examples of artificial compound feeds include animal ingredients such as fish meal, casein, and octopus intestine meal; vegetable ingredients such as soybean meal, wheat flour, and starch; -20- Bunting Distinguishment Continued 1239846 (15) Feed Yeast and other microbial raw materials; cod liver oil, squid liver oil and other animal fats; soybean oil, vegetable oils and vegetable fats; and vitamins, minerals, amino acids, acidulants, etc. as raw materials for artificial compound feed. There is also feed for fish such as minced fish. The feed manufacturing method of the present invention is not particularly limited, and its blending may be based on general feed. What is necessary is just to contain the aforementioned active ingredient related to the present invention which has an enhancement effect of NGF in the manufactured feed. In addition, the aforementioned active ingredient related to the present invention having an effect of enhancing NGF production may be directly added to a swimming pool, a sink, a holding bucket, or water or seawater for distant breeding, and the target organism may be immersed therein for administration. This impregnation method is particularly effective when the feed intake of the target organism is low. The aforementioned active ingredient related to the present invention, which has the effect of enhancing NGF production in water or sea water, is not limited in concentration, and may be used depending on the purpose. Ideally, a ratio of 0.00001 to 1% by weight is appropriate. In addition, a beverage containing the aforementioned effective ingredient of the present invention having an effect of enhancing NGF production is a breeding beverage, which can be ingested by a target organism. The concentration of the NGF production-enhancing effect in the beverage is not particularly limited in the present invention, and the concentration of the aforementioned active ingredient can be used according to the purpose, and a ratio of 0.0001 to 20% by weight is appropriate. Biofeeding agents containing the aforementioned effective ingredients of the present invention with an effect of enhancing NGF production, such as immersion agents, feed additives, and beverage additives, can be manufactured by the compounding and manufacturing methods of individual announcements. The content of the active ingredient in the biofeeding agent is not particularly limited as long as it can achieve the desired effect of the present invention. Although the organisms applicable to the present invention are not limited, examples of breeding animals include horses-21-· · · · * *-· · · «^ J f * · Invention Description Continued 1239846 (16) , Sheep, goats, road wheels, Luoma and other domestic animals; mice, mice, guinea pigs, white rabbits and other experimental animals; hard, duck, turkey, ostrich and other poultry; · Lion fish, green tongs, red tongs, catfish, horse mackerel, aquarium fish, warp fish. Trout, puffer fish, catfish, mud chain, catfish and other fish; crustaceans such as prawns, black tigers, prawns, pike crabs, etc .; shellfish such as abalone, snails, sea fans, oysters; and examples of pets include dogs, Cats, etc. can be widely used for land and water animals. It is possible to ingest a feed containing the aforementioned active ingredient used in the present invention with an enhancement effect of NGF production, or to immerse a target organism in a liquid containing the aforementioned active ingredient used in the present invention with an enhancement effect of NGF production. Maintain or improve the physical condition of livestock, laboratory animals, poultry, fish, shellfish, pets, etc. Furthermore, in another form of the present invention, the present invention is provided in the manufacture of a therapeutic or preventive agent for a disease that requires enhanced NGF production, an NGF production enhancer, and food, beverage, or feed for the enhancement of NGF production. Related use of the aforementioned active ingredients. Relevant usage patterns include the aforementioned therapeutic or preventive agents, NGF production enhancers, and NGF production enhancement foods, beverages, or the aforementioned use forms of active ingredients in the manufacture of feed. For example, in the manufacture of a therapeutic agent, a preventive agent, or an NGF production enhancing agent for enhancing the disease required for NGF production, the use of the aforementioned active ingredients is based on the solid form of the aforementioned tablets, granules, powders, powders, capsules, etc. The use of liquid preparations such as pharmaceutical preparations, liquid preparations, suspensions, emulsions and the like, as well as the production of dry products which are not liquid but are added by using an appropriate support before use are exemplified. -22- zr Λ,-'' ^ 'ί Description of the invention continued on 1239846 (23) The industrial use is possible. The present invention is about the use of mushroom extracts containing water as an active ingredient for the treatment or prevention of nerves. Medicines, foods, beverages or feeds that are effective for diseases caused by nutrient factors.

該醫藥對癡呆症及神經障礙等必需要有神經營養因子 產生增強之疾病的治療劑或預防劑有用。由於該食品或飲 料可經曰常飲食品攝取，可使需要神經營養因子產生增強 之疾病的症狀改善。還有，該飼料由於神經營養因子產生 增強作用，對生體之恆常性的維持亦有用。 -29-This medicine is useful as a therapeutic or preventive agent for diseases that require increased production of neurotrophic factors, such as dementia and neurological disorders. Since the food or drink can be ingested through regular food and drink, the symptoms of diseases requiring enhanced neurotrophic factor production can be improved. In addition, the feed has a strengthening effect due to neurotrophic factors, and is also useful for maintaining the constancy of the body. -29-

Claims (1)

2號專利申請案 列範圍替換本(94年3月） 拾、申請專利範圍 1. 一種神經營養因子產生增強劑，其特徵在含有蕈類之 水萃取物為有效成分。 2. 如申請專利範圍第1項之神經營養因子產生增強劑， 其中蕈類係無蕈褶目以及/或傘菌目。 3. 如申請專利範圍第2項之神經營養因子產生增強劑， 其中無蕈褶目蕈類係猴頭菇及/或舞茸，傘菌目蕈類 係選自由洋菇、椎茸、杏鮑菇、金針菇及玉蕈所構成 之群之一種以上者。 4. 如申請專利範圍第1〜3項中任一項之神經成長因子產 生增強劑，其係用於治療須要神經營養因子產生增強 之疾病。 5. —種神經營養因子產生增強用食品，其特徵在於含蕈 類之水萃取物。 6. 如申請專利範圍第5項之神經營養因子產生增強用食 品，其中蕈類係無蕈褶目以及/或者傘菌目。 7. 如申請專利範圍第6項之神經營養因子產生增強用食 品，其中無蕈褶目蕈類係猴頭菇及/或舞茸，傘菌目 蕈類係選自由洋菇、椎茸、杏鮑菇、金針菇及玉蕈所 構成之群之一種以上者。 8.如申請專利範圍第5〜7項中任一項之神經營養因子產 生增強用食品，其為一種飲料。Replacement of the scope of patent application No. 2 (March 94) Scope of application and patent application 1. A neurotrophic factor production enhancer, characterized in that the water extract containing mushrooms is an active ingredient. 2. The neurotrophic factor production enhancer according to item 1 of the scope of the patent application, wherein the mushrooms are free of Mycaria and / or Agaricida. 3. If the neurotrophic factor production enhancer of item 2 of the patent application scope, wherein the mushroom-free mushrooms are Hericium erinaceus and / or Maitake mushrooms, and the agaric mushrooms are selected from the group consisting of Pleurotus, Shiitake, Pleurotus , Flammulina velutipes and Jade Mushrooms. 4. If the nerve growth factor production enhancer according to any one of the scope of application for patents 1 to 3, it is used to treat diseases that require enhanced neurotrophic factor production. 5. A food for enhancing neurotrophic factor production, which is characterized by a water extract containing mushrooms. 6. The neurotrophic factor production-enhancing food according to item 5 of the scope of the patent application, wherein the mycorrhizal line is agaric and / or agaric. 7. If the food for enhancing neurotrophic factor production in item 6 of the patent application scope, wherein the mushroom-free mushrooms are Hericium erinaceus and / or Maitake, and the agaric mushrooms are selected from the group consisting of Pleurotus ostreatus, Shiitake, and Pleurotus One or more groups of mushrooms, enoki mushrooms and jade mushrooms. 8. The neurotrophic factor production enhancing food according to any one of claims 5 to 7, which is a beverage. 1239846 9. 一種神經營養因子產生增強用飼料，其特徵在於含蕈 類之水萃取物。 10. 如申請專利範圍第9項之神經營養因子產生增強用飼 料，其中蕈類係無蕈褶目以及/或者傘菌目。 11. 如申請專利範圍第10項之神經營養因子產生增強用 飼料，其中無蕈褶目蕈類係猴頭菇及/或舞茸，傘菌 目蕈類係選自由洋菇、椎茸、杏鮑菇、金針菇及玉蕈 所構成之群之一種以上者。1239846 9. A neurotrophic factor production enhancing feed characterized by a water extract containing mushrooms. 10. The neurotrophic factor production-enhancing feed according to item 9 of the scope of the patent application, wherein the mycorrhizal line is agaric and / or agaric. 11. If the neurotrophic factor production-enhancing feed for item 10 of the application is patented, wherein the mushroom-free mushrooms are Hericium erinaceus and / or Maitake, and the agaric mushrooms are selected from the group consisting of Pleurotus ostreatus, Shiitake, and Pleurotus One or more groups of mushrooms, enoki mushrooms and jade mushrooms.
TW091115842A 2001-07-16 2002-07-16 Remedies comprising water extracts of a mushrooms as an effective ingredient TWI239846B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001215524 2001-07-16

Publications (1)

Publication Number Publication Date
TWI239846B true TWI239846B (en) 2005-09-21

Family

ID=19050149

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091115842A TWI239846B (en) 2001-07-16 2002-07-16 Remedies comprising water extracts of a mushrooms as an effective ingredient

Country Status (7)

Country Link
US (1) US20040175396A1 (en)
EP (1) EP1415658A4 (en)
JP (1) JP4410555B2 (en)
KR (1) KR20040018460A (en)
CN (1) CN1529610A (en)
TW (1) TWI239846B (en)
WO (1) WO2003007977A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4686116B2 (en) * 2003-05-01 2011-05-18 株式会社雪国まいたけ Neurotrophic factor-like agent
JP2005325096A (en) * 2004-04-16 2005-11-24 Taisho Pharmaceut Co Ltd Monoamine reintake inhibitor compounded with grifola frondosa
WO2006128085A2 (en) * 2005-05-27 2006-11-30 The Trustees Of Columbia University In The City Of New York Cadherin-11-mediated modulation of hair growth
DE102005031364A1 (en) * 2005-06-30 2007-01-11 Ernst-Moritz-Arndt-Universität Greifswald Free radical scavengers for food supplements, osteoporosis treatment, plant strengtheners, cosmetics and pharmaceuticals contain terrestrial fungus extract, microalgal biomass and fungal biopolymer from Basidomycetes
US20100150955A1 (en) * 2005-08-09 2010-06-17 Hiroshi Endo Method of Producing Extract Derived From Lyophyllum Ulmarium
JP5144112B2 (en) * 2007-04-19 2013-02-13 野田食菌工業株式会社 Brain protectant
JP5444618B2 (en) * 2008-02-05 2014-03-19 株式会社リコム Human adrenergic β3 receptor agonist, food and medicine containing the same
US20090220667A1 (en) * 2008-03-03 2009-09-03 Daniel Johnson Herbal formulations and methods for supplementing caffeinated beverages
JP2009263344A (en) * 2008-03-31 2009-11-12 Cci Corp Fat cell differentiation-promoting agent
CN107456466A (en) * 2009-04-29 2017-12-12 培力(香港)健康产品有限公司 Neuroprotective glossy ganoderma composition and its application method
CN105707491A (en) * 2016-03-17 2016-06-29 四川汪氏动物保健有限责任公司 Nutritional cream for pet dogs or cats and preparation method thereof
WO2019131444A1 (en) 2017-12-26 2019-07-04 花王株式会社 Cognitive function improvement agent
JP2019112364A (en) * 2017-12-26 2019-07-11 花王株式会社 Motion regulation function improver
TWI771561B (en) * 2019-01-30 2022-07-21 葡萄王生技股份有限公司 Use of preparing a pharmaceutical composition for improving myelination of central nervous system by hericium erinaceus mycelia extract
PL432076A1 (en) * 2019-12-04 2021-06-14 Uniwersytet Jagielloński Mushroom-selenium feed additive, its production and use in improving the condition of livestock

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0772157B2 (en) * 1991-02-21 1995-08-02 カゴメ株式会社 Benzyl alcohol derivative, PGE2 production inhibitor and NGF production inducer containing the same as active ingredient
JPH0826010B2 (en) * 1991-03-02 1996-03-13 カゴメ株式会社 Chroman derivative, PGE2 production inhibitor and NGF production inducer containing the same as active ingredient
JP3515139B2 (en) * 1993-02-08 2004-04-05 東和化成工業株式会社 Lectin purification method using lactitol
JP2657883B2 (en) * 1993-03-04 1997-09-30 カゴメ株式会社 Sheatan derivative, nerve growth factor production inducer containing the same as active ingredient, and antibacterial agent
JPH0769961A (en) * 1993-08-31 1995-03-14 Kagome Co Ltd Cyathane derivative, and neuro growth factor production inducing agent and antimicrobial agent using the same as active component
JPH08319240A (en) * 1995-05-25 1996-12-03 Fuji Seito Kk Enzyme-inhibiting agent and food product having enzyme-inhibitory action
JPH0919270A (en) * 1995-07-04 1997-01-21 Kagome Co Ltd Production of food or beverage containing cultured mycelia of hericium erinaceum
JPH0959172A (en) * 1995-08-25 1997-03-04 Kagome Co Ltd Nfg producing inducer and beverage and food
GB9626539D0 (en) * 1996-12-20 1997-02-05 Univ Liverpool A method of enhancing the rate of transfection of cells
JP4293294B2 (en) * 1998-04-24 2009-07-08 藤原 道弘 Dementia remedy
CN1101224C (en) * 1999-10-20 2003-02-12 林德球 Injection for giving up addiction

Also Published As

Publication number Publication date
EP1415658A4 (en) 2005-06-08
KR20040018460A (en) 2004-03-03
EP1415658A1 (en) 2004-05-06
US20040175396A1 (en) 2004-09-09
WO2003007977A1 (en) 2003-01-30
JPWO2003007977A1 (en) 2004-11-04
JP4410555B2 (en) 2010-02-03
CN1529610A (en) 2004-09-15

Similar Documents

Publication Publication Date Title
TWI239846B (en) Remedies comprising water extracts of a mushrooms as an effective ingredient
JP5112865B2 (en) Composition for preventing or treating hemoglobinuria or myoglobinuria
JP2014009216A (en) Composition containing peptide and/or free amino acid
JPWO2003006037A1 (en) Therapeutic agent
JP2007051136A (en) Use of d-psicose for inhibiting d-fructose concentration rise in blood
WO2015137387A1 (en) Muscle enhancing drug
TWI784004B (en) Use of acetic acid and/or acetate salts in the manufacture of compositions for improving brain function
JP2005336176A (en) Body fatigue restorer
JP6252922B2 (en) Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof
JP2007238581A (en) Composition for ameliorating arthritis
JP6024942B2 (en) Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof
AU2016317621A1 (en) Composition for muscle building and method for building muscle
JPWO2008123417A1 (en) Anti-fatigue
EP3302095B1 (en) Novel marine protein hydrolysates and uses thereof
JP2009254242A (en) Novel sweetener having sugar-like taste, method for producing the same, and use of the sweetener
CN113491334B (en) nutritional composition
WO2023218868A1 (en) Sympathetic nerve activator and composition for sympathetic nerve activation
TW202348222A (en) Myoblast proliferation promoting agent, composition for promoting myoblast proliferation, muscular atrophy inhibiting agent, and composition for inhibiting muscular atrophy
JP2023103165A (en) Atp production promoter, anti-inflammatory agent, and food/drink product
JP5943516B2 (en) Sweetener for improving biological function comprising D-sorbose as an active ingredient
WO2006025329A1 (en) Antitumor agent

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees